---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-257993"
form_type: "8-K"
ticker: "IVVD"
cik: "0001832038"
company_name: "Invivyd, Inc."
filed_at: "2024-11-14T23:59:59+00:00"
generated_at: "2026-05-30T00:35:42.152963+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Invivyd Q3 2024 net product revenue $9.3M but net loss widens to $60.7M; cash $106.9M

## Summary
- PEMGARDA net product revenue $9.3M, up from $2.3M in Q2 2024; not at previously anticipated rates.
- Net loss $60.7M ($0.51 EPS) vs $39.4M ($0.36 EPS) in Q3 2023; R&D spending rose to $57.9M.
- Cash and equivalents $106.9M; year-end 2024 cash expected at least $65M, targeting near-term profitability.
- NEJM published Invivyd letter on PEMGARDA immunobridging pathway; Ho Lab letter with conflicting in vitro data published same day.
- VYD2311 Phase 1 dosing began August 2024; preliminary data readout expected late Q4 2024.

## SEC filing metadata
- accession: 0001193125-24-257993
- form_type: 8-K
- ticker: IVVD
- cik: 0001832038
- company_name: Invivyd, Inc.
- filed_at: 2024-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1832038/000119312524257993/0001193125-24-257993-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1832038/000119312524257993/d894288d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-257993
- JSON: https://secwatch.observer/filing/0001193125-24-257993.json
- Plain text: https://secwatch.observer/filing/0001193125-24-257993.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.